Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
6 clusters · 15 sources · 43 days · First seen · Last updated
Research into diabetic kidney disease treatments
Overview
Scientific research into diabetic kidney disease (DKD) is focusing on novel therapeutic targets, improved monitoring markers, and optimized medication timing. Studies in the ‘Chinese Journal of Natural Medicines’ suggest the plant compound hederagenin may protect kidney health by activating anti-aging genes to combat cellular senescence. Additionally, researchers are investigating protein tyrosine phosphatases (PTP) as potential therapeutic targets.
Clinical observations emphasize combining medication classes—such as RAS blockers, SGLT2 inhibitors, mineralocorticoid receptor antagonists, and GLP-1 receptor agonists—to delay dialysis. While the BESTMED study indicates GLP-1 and SGLT-2 inhibitors can slow renal decline more effectively than traditional therapies, concerns persist regarding the off-label use of GLP-1 weight-loss drugs and risks like ketoacidosis.
Newer research highlights advancements in monitoring and administration. In South Korea, non-albumin proteinuria (NAP) has been identified as a potential marker for monitoring patient response to finerenone. Furthermore, data from National Taiwan University Hospital suggests that the timing of SGLT-2 inhibitor administration may be critical for patients recovering from acute kidney injury.
At the American Society of Nephrology’s Kidney Week 2026, clinical trial data for finerenone showed it slowed eGFR decline in non-diabetic CKD patients, even when used alongside SGLT2 inhibitors. A phase 2 trial of balcinrenone combined with dapagliflozin also demonstrated reduced systolic blood pressure in stage 3 CKD patients. Regarding GLP-1 receptor agonists, new data on elecoglipron indicated a reduction in urine albumin-to-creatinine ratio (UACR) in type 2 diabetes patients.
In geriatric populations, real-world data involving over 10,000 adults aged 80 or older suggested SGLT2 inhibitor therapy was linked to an 18% reduction in all-cause mortality, though risks for acute kidney injury and certain cardiac events remain. Digital health advancements, such as using large language models (LLMs) for prior authorization letters and risk-stratification models, were also highlighted to improve therapy uptake.
Entities
Chinese Journal of Natural Medicines · BESTMED study · National Taiwan University Hospital · FIND-CKD trial · ASN Kidney Week 2026
Timeline
-
[HEALTH] 7 sourcesASN Kidney Week 2026 highlights new therapies and digital tools for CKD
Research presented at ASN Kidney Week 2026 highlights new drug data for finerenone and SGLT2 inhibitors, advancements in GLP-1 receptor agonists, and the role of AI and point-of-care testing in CKD care.
-
[HEALTH] 2 sourcesContinuous glucose monitoring may benefit kidney health in diabetes patients
A study published in JAMA Network Open suggests that sustained real-time continuous glucose monitoring may improve long-term glycemic control and kidney health in high-risk type 2 diabetes patients.
-
[HEALTH] 2 sourcesGLP-1 and SGLT-2 medications show potential in slowing kidney disease
New studies show GLP-1 and SGLT-2 medications can significantly slow kidney disease progression, though experts warn of risks from unsupervised use for weight loss among individuals with normal BMIs.
-
[HEALTH] 2 sourcesMedical advancements offer new hope for managing chronic kidney disease
New medical findings suggest plant compounds like hederagenin and combinations of drug classes such as SGLT2 inhibitors and RAS blockers can help prevent kidney aging and delay dialysis in diabetic patients.
-
[HEALTH] 2 sourcesResearch explores new markers and timing for diabetes kidney treatments
New studies suggest non-albumin proteinuria may better track finerenone response in diabetic kidney disease, while early SGLT-2 inhibitor use may improve outcomes for patients recovering from acute kidneyinjury
-
[HEALTH] 2 sourcesResearch explores new therapies for diabetic kidney disease
New research explores plant compounds like hederagenin and protein tyrosine phosphatase inhibitors as potential treatments to prevent or slow diabetic kidney disease and cellular senescence.
Sources
ad-hoc-news.de · consultantlive.com · diocesedeanapolis.org.br · emjreviews.com · ghananewss.com · knowridge.com · lomazoma.com · ma-clinique.fr · mdmag.com · medisite.fr · myjoyonline.com · news-medical.net · pharmacytimes.com · timelines.issarice.com · upreg.fr
This summary has been updated 5 times: see revision history